SINGULAR GENOMICS SYSTEMS IN (OMIC) Fundamental Analysis & Valuation

NASDAQ:OMIC • US82933R3084

Current stock price

20.01 USD
+0.05 (+0.25%)
Last:

This OMIC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. OMIC Profitability Analysis

1.1 Basic Checks

  • In the past year OMIC has reported negative net income.
  • In the past year OMIC has reported a negative cash flow from operations.
  • In the past 5 years OMIC always reported negative net income.
  • OMIC had a negative operating cash flow in each of the past 5 years.
OMIC Yearly Net Income VS EBIT VS OCF VS FCFOMIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

  • OMIC has a worse Return On Assets (-46.27%) than 87.50% of its industry peers.
  • OMIC has a worse Return On Equity (-70.04%) than 73.21% of its industry peers.
Industry RankSector Rank
ROA -46.27%
ROE -70.04%
ROIC N/A
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
OMIC Yearly ROA, ROE, ROICOMIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for OMIC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMIC Yearly Profit, Operating, Gross MarginsOMIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

5

2. OMIC Health Analysis

2.1 Basic Checks

  • OMIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for OMIC has been reduced compared to 1 year ago.
  • Compared to 1 year ago, OMIC has a worse debt to assets ratio.
OMIC Yearly Shares OutstandingOMIC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
OMIC Yearly Total Debt VS Total AssetsOMIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -3.44, we must say that OMIC is in the distress zone and has some risk of bankruptcy.
  • OMIC's Altman-Z score of -3.44 is on the low side compared to the rest of the industry. OMIC is outperformed by 85.71% of its industry peers.
  • OMIC has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
  • OMIC has a Debt to Equity ratio of 0.04. This is in the better half of the industry: OMIC outperforms 69.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -3.44
ROIC/WACCN/A
WACC11.59%
OMIC Yearly LT Debt VS Equity VS FCFOMIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

  • OMIC has a Current Ratio of 7.37. This indicates that OMIC is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 7.37, OMIC belongs to the top of the industry, outperforming 83.93% of the companies in the same industry.
  • OMIC has a Quick Ratio of 6.67. This indicates that OMIC is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 6.67, OMIC belongs to the best of the industry, outperforming 83.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.37
Quick Ratio 6.67
OMIC Yearly Current Assets VS Current LiabilitesOMIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

4

3. OMIC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 8.62% over the past year.
  • The Revenue has been growing slightly by 2.54% in the past year.
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
Revenue 1Y (TTM)2.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.12%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.54% on average over the next years. This is quite good.
  • OMIC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 108.68% yearly.
EPS Next Y11.81%
EPS Next 2Y8.6%
EPS Next 3Y9.54%
EPS Next 5YN/A
Revenue Next Year9.93%
Revenue Next 2Y96.89%
Revenue Next 3Y108.68%
Revenue Next 5YN/A

3.3 Evolution

OMIC Yearly Revenue VS EstimatesOMIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 5M 10M 15M 20M
OMIC Yearly EPS VS EstimatesOMIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

0

4. OMIC Valuation Analysis

4.1 Price/Earnings Ratio

  • OMIC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OMIC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMIC Price Earnings VS Forward Price EarningsOMIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMIC Per share dataOMIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.6%
EPS Next 3Y9.54%

0

5. OMIC Dividend Analysis

5.1 Amount

  • No dividends for OMIC!.
Industry RankSector Rank
Dividend Yield N/A

OMIC Fundamentals: All Metrics, Ratios and Statistics

SINGULAR GENOMICS SYSTEMS IN

NASDAQ:OMIC (2/20/2025, 8:00:01 PM)

20.01

+0.05 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-12
Earnings (Next)03-17
Inst Owners54.77%
Inst Owner Change-72.02%
Ins Owners14.13%
Ins Owner Change0%
Market Cap50.63M
Revenue(TTM)2.67M
Net Income(TTM)-86.32M
Analysts80
Price Target12.7 (-36.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.66%
Min EPS beat(2)5.17%
Max EPS beat(2)18.16%
EPS beat(4)4
Avg EPS beat(4)9.18%
Min EPS beat(4)4.76%
Max EPS beat(4)18.16%
EPS beat(8)8
Avg EPS beat(8)13.23%
EPS beat(12)12
Avg EPS beat(12)13.65%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)14.44%
Min Revenue beat(2)-51.75%
Max Revenue beat(2)80.64%
Revenue beat(4)3
Avg Revenue beat(4)20.95%
Min Revenue beat(4)-51.75%
Max Revenue beat(4)80.64%
Revenue beat(8)3
Avg Revenue beat(8)-8.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.5%
EPS NY rev (1m)0.83%
EPS NY rev (3m)2.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.99
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-35.09
EYN/A
EPS(NY)-32.25
Fwd EYN/A
FCF(TTM)-31.96
FCFYN/A
OCF(TTM)-31.79
OCFYN/A
SpS1.05
BVpS48.72
TBVpS48.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -46.27%
ROE -70.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.24%
Cap/Sales 15.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.37
Quick Ratio 6.67
Altman-Z -3.44
F-Score3
WACC11.59%
ROIC/WACCN/A
Cap/Depr(3y)235.15%
Cap/Depr(5y)229.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
EPS Next Y11.81%
EPS Next 2Y8.6%
EPS Next 3Y9.54%
EPS Next 5YN/A
Revenue 1Y (TTM)2.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.12%
Revenue Next Year9.93%
Revenue Next 2Y96.89%
Revenue Next 3Y108.68%
Revenue Next 5YN/A
EBIT growth 1Y5.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.13%
EBIT Next 3Y3.57%
EBIT Next 5YN/A
FCF growth 1Y9.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.96%
OCF growth 3YN/A
OCF growth 5YN/A

SINGULAR GENOMICS SYSTEMS IN / OMIC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SINGULAR GENOMICS SYSTEMS IN (OMIC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to OMIC.


What is the valuation status for OMIC stock?

ChartMill assigns a valuation rating of 0 / 10 to SINGULAR GENOMICS SYSTEMS IN (OMIC). This can be considered as Overvalued.


Can you provide the profitability details for SINGULAR GENOMICS SYSTEMS IN?

SINGULAR GENOMICS SYSTEMS IN (OMIC) has a profitability rating of 0 / 10.


What is the expected EPS growth for SINGULAR GENOMICS SYSTEMS IN (OMIC) stock?

The Earnings per Share (EPS) of SINGULAR GENOMICS SYSTEMS IN (OMIC) is expected to grow by 11.81% in the next year.